



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification³ :G01N 33/54; C12N 5/00
C12P 21/00

A1

(11) International Publication Number:

WO 83/ 04104

(43) International Publication Date:

24 November 1983 (24.11.83)

(21) International Application Number: PCT/US83/00741

(22) International Filing Date: 16 May 1983 (16.05.83)

(31) Priority Application Number: 379,704

(32) Priority Date: 19 May 1982 (19.05.82)

(33) Priority Country: US

(71)(72) Applicant and Inventor: GAY, Steffen [US/US];
1100 Beacon Parkway East, Regency Villa 102, Bir-
mingham, AL 35209 (US).(74) Agent: MISROCK, S., Leslie; Pennie & Edmonds, 330
Madison Avenue, New York, NY 10017 (US).(81) Designated States: AT (European patent), AU, BE (Eu-
ropean patent), CH (European patent), DE (European
patent), DK, FR (European patent), GB (European
patent), LU (European patent), NL (European pa-
tent), NO, SE (European patent).

Published

With international search report.(54) Title: IN VITRO DIAGNOSTIC METHODS USING MONOCLONAL ANTIBODIES AGAINST CONNec-
TIVE TISSUE PROTEINS

(57) Abstract

Monoclonal antibodies against connective tissue proteins which can be used to determine the collagen profile of bio-
logical fluid samples, cytological samples and histological samples. Combinations of these monoclonal antibodies may be
used for diagnosis and therapy.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	LI	Liechtenstein
AU	Australia	LK	Sri Lanka
BE	Belgium	LU	Luxembourg
BR	Brazil	MC	Monaco
CF	Central African Republic	MG	Madagascar
CG	Congo	MR	Mauritania
CH	Switzerland	MW	Malawi
CM	Cameroon	NL	Netherlands
DE	Germany, Federal Republic of	NO	Norway
DK	Denmark	RO	Romania
FI	Finland	SE	Sweden
FR	France	SN	Senegal
GA	Gabon	SU	Soviet Union
GB	United Kingdom	TD	Chad
HU	Hungary	TG	Togo
JP	Japan	US	United States of America
KP	Democratic People's Republic of Korea		

IN VITRO DIAGNOSTIC METHODS USING MONOCLONAL ANTIBODIES
AGAINST CONNECTIVE TISSUE PROTEINSINTRODUCTION

5 This invention relates to the production of
antibodies specific for connective tissue proteins and,
more particularly, to the production of monoclonal
antibodies by fused cell hybrids against human collagens
and enzymes involved in collagen degradation. Collagen is
by far the most prevalent human protein, constituting
almost half of the total body protein. The prolific
10 research in recent years in the area of collagen
biochemistry has demonstrated that there are at least six
genetically distinct collagens and several related
collagen-degrading enzymes.

15 The collagen profile, i.e., the types of distinct
collagens and collagen-associated proteins present, their
distribution in the tissue, and the concentration ratios
among the distinct types, of any given tissue or body fluid
sample varies with the tissue or fluid source. Moreover,
20 the collagen profile of a tissue or fluid sample also
varies with the physiological or pathological state of its
source. In fact, there are numerous connective tissue
disorders and other pathological conditions in which
changes in the collagen profile occur, eventually resulting
25 in such large scale tissue alterations as to cause organ
impairment. Hence, a specific and reliable means for
detecting and/or quantitatively measuring changes in
collagen types and distribution in tissue and body fluids
is extremely useful for diagnostic evaluations of the stage
30 of and specific organ involvement in certain diseases.
Furthermore, the detection and/or quantitative measurement
of different types of collagens and collagen-associated
enzymes in body fluids provides a means for monitoring
therapies that result in a release of collagens and
35

collagen-associated enzymes into body fluids upon the eradication of cells, such as tumor cells, against which the drug is targeted.

5

The use of monoclonal antibodies against connective tissue proteins to establish the collagen profile of histological, cytological and biological fluid samples is a novel and advantageous approach to disease diagnosis and therapy monitoring. Because of the high
10 specificity and sensitivity of monoclonal antibodies, early detection of certain collagen-related pathological conditions is possible as is early assessment of the efficacy of certain therapeutic programs. To achieve these goals, the invention provides: (1) a method for repeatedly
15 producing large quantities of monospecific antibodies against distinct connective tissue proteins and (2) procedures for using the monoclonal antibodies individually or in combination as clinical probes for diagnosis and
20 therapy monitoring. The potential prognostic importance of early and accurate disease diagnosis and determination of the usefulness of certain therapies using the methods of this invention is highly significant.

25

2. BACKGROUND OF THE INVENTION

2.1. MONOCLONAL ANTIBODIES

Kohler and Milstein are generally credited with
30 having devised the technique that successfully resulted in the formation of the first monoclonal antibody-producing hybridomas [G. Kohler and C. Milstein, Nature 256:495-497 (1975); Eur. J. Immunol. 6:511-519 (1976)]. The monoclonal antibodies produced by hybridomas are highly specific
35 immunoglobulins of a single type. The single type of immunoglobulin secreted by a hybridoma is specific to one

and only one antigenic determinant on an antigen, a complex molecule having a multiplicity of antigenic determinants. Hence, monoclonal antibodies raised against a single antigen may be distinct from each other depending on the
5 determinant that induced their formation; but for any given clone, all of the antibodies it produces are identical.

Monoclonal methods are generally applicable and have been used to produce antibodies to antigens other than
10 the sheep red blood cells used by Kohler and Milstein. For instance, it has been reported that monoclonal antibodies have been raised against tumor cells [U.S. Pat. No. 4,172,124] and viruses [U.S. Pat. No. 4,196,265]. The
15 production of monoclonal antibodies against certain collagens, procollagens (natural precursors of collagens) and a collagen-associated glycoprotein has also been reported. Linsenmayer et al. reported using the cell
hybridization technique to produce monoclonal antibodies against chick Type I collagen [Proc. Natl. Acad. Sci.
20 U.S.A. 76(8):3703-3707 (1979)]; Linsenmayer and Hendrix later reported having produced a monoclonal antibody specific for chick Type II collagen [Biochem. Biophys. Res. Commun. 92:440-446 (1980)]. Both antibodies have been used
25 for biochemical and cytological studies of extracellular matrices involved in the morphogenesis of the embryonic chick. Walsh et al. [Dev. Biol. 84:121-132 (1981)] have reported producing a monoclonal antibody against human fibronectin, a collagen-associated glycoprotein, as part of
an investigation to define human muscle surface antigens.
30 The biochemical and immunological characterization of monoclonal antibodies specific for human collagens, Types I, III and IV, and human procollagens Types I and III has recently been reported [N. SundarRaj et al., J. Cell Biol. (Abstr.) 91(2):8027 (1981)]. Finally, a monoclonal
35 antibody against the collagen degrading enzyme elastase has



been used to study the pathogenesis of inflammatory joint disease [S. Gay et al., VIIIth Southeastern Meeting, Amer. Rheum. Assoc., Abstr. 1, (1981)].

5

2.2. CONNECTIVE TISSUE PROTEINS

Information on the biochemistry of the genetically-distinct collagen types and their role in biological processes has grown prolifically in recent years [P. Bornstein and H. Sage, Ann. Rev. Biochem. 49:957-1003 (1980); S. Gay and E. Miller, Collagen in the physiology and pathology of connective tissue, Gustav Fischer Verlag, New York (1978)]. Currently, the known collagens can be subdivided into four categories based on their histological distribution [S. Gay et al., Arthritis and Rheumatism 23(8):937-941 (1980)]. Each type of collagen has as its biosynthetic precursor a procollagen molecule which differs from the mature collagen molecule insofar as it has additional amino acid sequences at the amino and carboxy termini of each chain that are eventually cleaved by specific processing enzymes.

The interstitial collagen molecules comprise the majority of all the connective tissue proteins and account for nearly all fibrillar tissue components. This class of collagens represents four distinct molecular species: (1) the Type I collagen molecule which exhibits the chain composition $[\alpha 1(I)]_2 \alpha 2(I)$. Fibers derived from Type I collagen are found throughout the entire organism primarily in supporting tissues which normally exhibit very little distensibility under physical stress; (2) the Type I-trimer collagen molecule which is comprised of three identical $\alpha 1(I)$ chains. This molecule has been described in certain chondrocyte cultures and other experimental systems, but its existence in normal tissue has not been firmly

established; (3) the Type II collagen molecule which contains three $\alpha 1(\text{II})$ chains. In most instances this species forms relatively thin fibrils and displays a tissue distribution restricted predominantly to cartilaginous structures such as articular cartilage and nucleus pulposus and to certain parts of the embryonic eye; and (4) the Type III collagen molecule which is composed of three $\alpha 1(\text{III})$ chains. The fibrils formed by these molecules are usually found in a reticular network. The latter meshwork apparently contains in addition to Type III molecules certain quantities of a form of Type III procollagen indicating that the conversion of Type III procollagen to Type III collagen is incomplete. These procollagen molecules participate in the formation of fine non-striated filaments which are associated with the Type III fibrils.

The basement membrane collagens include at least two distinct collagen chains, the $\alpha 1(\text{IV})$ and $\alpha 2(\text{IV})$, which exhibit unique compositional features. The configuration of these chains within native collagen molecules is presently unknown. These collagens appear to be universally distributed as components of the morphologically distinct epithelial and endothelial basement membranes.

The pericellular collagens commonly referred to as Type V collagen contain three distinct chains, $\alpha 1(\text{V})$, $\alpha 2(\text{V})$ and $\alpha 3(\text{V})$, which combine to form a variety of molecular species. Histologically, they are more predominant in cells derived from the vascular system as compared to other tissues and appear to form a pericellular exocytoskeleton.

In certain tissues there are high molecular weight aggregates which upon disulfide bond reduction and



denaturation are found to contain unique collagenous subunits (Type VI collagen). These aggregates may serve as structural polypeptides linking collagenous sequences with noncollagenous sequences [D. Furuto and E. Miller, J. Biol. Chem. 255(1):290-295 (1980); D. Furuto and E. Miller, Biochem. 20:1635-1640 (1981)].

Procollagens and cross-linked collagen molecules are susceptible to attack by specific collagen-degrading enzymes collectively called collagenases; cleavage by such enzymes yields procollagen peptides and collagen peptides. For instance, elastase is a very distinct collagen-degrading enzyme which selectively cleaves Type III collagen, but not Type I collagen, and releases a distinct trimer peptide, $\alpha 1(\text{III})^B$. [C. Mainardi et al. J. Biol. Chem. 255(24):12006-12010 (1980)].

2.3 PATHOLOGICAL CONDITIONS INVOLVING CONNECTIVE TISSUE PROTEINS

Pathological conditions involving connective tissue proteins are numerous and can be grouped roughly into three categories: conditions resulting from overt trauma, heritable disorders, and disorders commonly called acquired diseases. The pathophysiology of connective tissue that is characteristic of these disorders has been reviewed by Gay and Miller [S. Gay and E. Miller, Collagen in the physiology and pathology of connective tissue, Gustav Fischer Verlag, New York (1978)].

Of the three categories of connective tissue pathology, it is in the acquired connective tissue disorders that changes in the collagen profile of afflicted tissues most notably occur as the disease progresses. The acquired disorders are pathophysiological



conditions in which large scale tissue alterations occur as the result of an apparent lack of coordination between collagen synthesis and degradation. The disorders include atherosclerosis, liver cirrhosis, lung fibrosis, bone marrow fibrosis, systemic progressive sclerosis, scleroderma, psoriasis, rheumatoid arthritis, osteoarthritis and certain benign and malignant tumors. For the most part, these conditions arise through fibroproliferative responses leading to an excessive accumulation of collagen in affected tissues though some disorders involve degenerative changes within previously normal connective tissues.

The patterns of collagen deposition in three different fibroproliferative disorders, atherosclerosis, liver fibrosis (or cirrhosis) and scleroderma of skin are quite similar and are illustrative of the types of changes in collagen profile that occur in the acquired connective tissue diseases. In the early stage of such pathological conditions, an increase in basement membrane collagen synthesis is first observed. The deposition of basement membrane matrix containing Type IV collagen is followed by a Type III collagen neosynthesis. The Type III collagen thereby forms the reticular network of granulation tissue. Finally the dense collagen fiber forms the scar tissue which is almost completely comprised of Type I collagen molecules [S. Gay, Ital. J. Gastroenterol. 12:30-32 (1980)].

A number of tumors such as the various kinds of fibromatoses elaborate matrices containing copious quantities of fibrous collagen. Malignant tumors such as the osteosarcomas or chondrosarcomas may also produce large amounts of collagenous matrix. In these disorders, the collagen produced generally reflects the cellular

origin of the tumor. Thus, osteosarcoma cells produce a matrix containing fibers derived from Type I molecules, whereas the fibrous elements of chondrosarcomas are
5 derived from Type II molecules, [K. Remberger and S. Gay, Z. Krebsforsch. 90:95-106 (1977)]. However, it is possible that less differentiated tumors may synthesize a number of different collagens. For instance, metastasized neoplastic mammary epithelial cells of breast carcinomas
10 retain the ability to synthesize Type IV (basement membrane) collagen [L.A. Liotta et al., The Lancet, July 21, 1979: 146-147].

Rheumatoid arthritis is an acquired disease
15 manifested by either fibroproliferative or degenerative changes in the connective tissue of diarthrodial joints. In the inflammatory-proliferative phase, rheumatoid synovial tissue is characterized by the synthesis and deposition of additional Type I and III collagens. The
20 blood vessels of the proliferating pannus tissue carry the bulk of vascular-derived Type V collagen. The endothelial basement membrane containing Type IV collagen often appears irregular, discontinuous, and sometimes multilamellated in the vessels of pannus tissue. The
25 altered basement membrane barrier is reflected by the cellular synovial exudate. The exudate contains phagocytes that exhibit inclusions of various collagens. The presence of different collagens in phagocytes of the synovial fluid is apparently due to degradation and
30 erosion of different parts of the joint due to proteolytic activity on the part of collagenases. Phagocytosis of the vessel-derived collagens such as Type IV collagen from endothelium as well as Type V collagen surrounding smooth muscle cells and pericytes may reflect at least in part
35 the degree of vascular necrosis. The presence of Type I and III collagen within the exudate cells suggests the

destruction of the synovial matrix. However, the demonstration of considerable amounts of Type III collagen may also reflect collagen neosynthesis as observed in other fibro-proliferative disorders. The existence of Type II collagen in the synovial phagocytes undoubtedly indicates the erosion of articular cartilage. From this discussion it is clear that the collagen profile of synovial exudate cells and synovial fluid can reflect the nature and extent of initial joint damage and the progress of the joint disease [S. Gay et al., Arthritis and Rheumatism 23(8):937-941 (1980)].

Osteoarthrosis is an example of a noninflammatory joint disorder that involves degenerative loss of the articular cartilage. During the early stages of osteoarthrosis, articular cartilage is characterized by a loss of proteoglycan aggregates, presumably due to the release of unusually large amounts of degradative enzymes, which results in demasking Type II collagen fibers on fibrillated surfaces [S. Gay and R.K. Rhodes, Osteoarthritis Symposium, pp. 43-44, Grune & Stratton, Inc. (1981)]. In general, the fibrillated surface persists and the initial clefts eventually extend into the deeper layers of articular cartilage due to the inefficient healing and repair capacity of cartilage tissue. Chondrocytes do proliferate and form clusters adjacent to the cartilage clefts. Although these chondrocytes apparently retain their capacity to form new proteoglycan aggregates, the capacity to synthesize new cartilage specific Type II collagen molecules appears to be greatly diminished or lost. Instead, a small deposition of fibrocartilaginous material comprised of collagen fibers derived from Type I molecules occurs. The switch from Type II collagen synthesis to Type I collagen synthesis appears to be an important step in the

pathogenesis of osteoarthritis and hence the presence of Type I collagen in biopsies can serve as an indicator of the progress of the disease.

5

2.4 BIOCHEMICAL APPROACHES TO THE STUDY OF COLLAGEN AND CONNECTIVE TISSUE PATHOLOGY

Investigations on collagen in pathological states have frequently taken the form of: solubility (extractability) determinations in an effort to discern the state or extent of cross-linking; analyses of tissue hydroxyproline content as a measure of total collagen content; and evaluations of the capacity for collagen synthesis based on specific activity determinations in both in vivo and in vitro labeling experiments. Each of these approaches is inherently limited and therefore has several disadvantages. Thus the solubility or extractability of the collagen in a given specimen is heavily dependent on the physical state of the specimen, is often quite low, and most probably reflects the nature rather than the extent of the collagen cross-links prevalent within the tissue. Also, hydroxyproline determinations may provide misleading values for total collagen content due to the presence of other hydroxyproline-containing proteins such as elastin or Clq, as well as the presence of varying proportions of the various collagens. With respect to the latter point, the Type III collagen molecule contains about 30% more hydroxyproline than the Type I collagen molecule. Therefore, the total collagen content of a given specimen cannot be related to hydroxyproline content unless a reasonably accurate estimate of the proportions of these collagens in the tissue is available. And finally, the in vivo as well as in vitro labeling experiments are often difficult to interpret since rates of collagen degradation

and pool sizes are not commonly evaluated. At best, then, these biochemical approaches provide only limited insight into the possible alterations in collagen chemistry and biosynthesis in diseased tissues. Moreover, they offer virtually no information with respect to the prevalence or disposition of the various collagens in such tissues, and hence are of limited or no diagnostic use.

10 2.5 IMMUNOLOGICAL APPROACHES TO THE STUDY OF
 COLLAGEN AND CONNECTIVE TISSUE PATHOLOGY

Even though the genetically distinct types of collagens are very similar to one another in their macromolecular structure, they are sufficiently different in their amino acid sequence to allow the production of specific antibodies. Antibodies can be raised against antigenic determinants located in five identifiable regions of collagen or procollagen molecules, specifically, the globular amino and carboxy termini of procollagen molecules, the non-helical termini of mature collagen molecules, the helical portion of collagen and procollagen molecules, and the central amino acid sequences of individual α -chains, obtained by denaturing collagen molecules. Thus, the antigenic regions in collagen consist both of sequential and conformational determinants.

Despite the weak antigenicity of collagen molecules, antibodies (in conventional antisera) have been successfully raised against distinct collagens, procollagens and collagen-associated proteins [Timpl et al., J. Immunol. Methods 18:165-182 (1977), U.S. Pat. No. 4,312,853; J. Risteli et al., Fresenius Z. Anal. Chem. 301:122 (1980)] and have proved to be exceedingly useful reagents in elucidating the precise distribution of the



various collagens in tissues and body fluids as well as in determining the capacity of certain cells to synthesize the various collagens. In fact, the information on the changes in collagen profiles which occurs during the connective tissue disorders discussed in Section 2.3 was obtained primarily through the use of immunohistological techniques and radioimmunoassays based on antibodies to the genetically distinct collagens.

While antibodies against collagens have been used mostly in connection with biological and biomedical research, the use of antibodies has also been suggested as a means for early clinical recognition of certain collagen-related diseases and other pathological conditions. A radioimmunoassay for Type III procollagen and Type III procollagen peptide has been reported by Timpl for the purpose of measuring these antigens in blood. Detection may indicate the presence of such possible disease states as liver cirrhosis or hepatitis [U.S. Pat. No. 4,312,853], which, at early stages, are often accompanied by the release of procollagen and procollagen peptide Type III into the serum and other body fluids. An immunohisto-chemical method for detecting Type IV (basement membrane) collagen-producing cells was reportedly used for the localization of single metastatic cells (which produce Type IV collagen and which could not be detected otherwise) in sections of lymph-nodes of breast cancer patients [L.A. Liotta et al., The Lancet, July 21, 1979:146]. Radioimmunoassays for two basement membrane proteins, 7S collagen (non-Type IV) and the non-collagenous protein laminin have been reported by J. Risteli et al. [Fresenius Z. Anal. Chem. 301:122 (1980)]. The proposed use was for monitoring basement membrane disorders (such as the microangiopathic lesions of diabetes mellitus) by measuring the amount of these

proteins circulating in the human blood stream.
Enzyme-linked immunoabsorbent assays have been developed
for types I, II, III, and IV collagen and for laminin and
5 fibronectin by using antibodies prepared in rabbits and
goats [S.I. Rennard et al., Anal. Biochem.
104:205-214(1980)].

Notably, all the antibodies used to detect the
10 presence of collagens and collagen-associated proteins in
body fluids and tissues and to study collagen distribution
during pathological states have been polyclonal antibodies
produced by conventional means. Since various levels of
cross-reacting antibodies may occur in the antisera, the
15 specificity of such antisera must be increased by
time-consuming immuno-adsorption procedures. [Timpl et
al., J. Immunol. Methods 18:165-182 (1977)].

Adaptation of monoclonal techniques to the
20 production of highly specific antibodies against the
genetically distinct collagens and other connective tissue
proteins for use in in vitro diagnostics and chemotherapy
monitoring represents a clear improvement over previous
immunological approaches to the detection of collagen-
25 related pathological conditions. The fused cell hybrids
made with these methods produce a single kind of antibody
specific for the collagen antigen of interest. Higher
titers of identical immunoglobulins are available in
essentially limitless supply since the antibody-producing
30 hybridomas can be cultured indefinitely in vitro or
propagated in mice or other laboratory animals.
Conventional methods for producing antibodies result in
preparations of less specific polyclonal antisera which
have to be purified extensively prior to use and can never
35 be reproduced identically. The monoclonal approach,
however, permits the quantitatively large-scale yet



inexpensive production of highly specific antibodies, requiring minimal purification, if any, in small-scale culture vessels or laboratory animals.

5

3. SUMMARY OF THE INVENTION

Prior to the present invention, applicant believes there has been no report of a clinically useful preparation of monoclonal antibodies specific for all the
10 known genetically distinct types of human collagens, collagen-associated enzymes and collagen peptide fragments resulting from enzymatic cleavage. Because collagen profiles of human body tissues and fluids change during
15 certain pathological conditions and during therapeutic regimens and because the changes can be detected by immunohistological and immunoserological techniques, the monoclonal antibodies of this invention represent a new in vitro means of early and accurate disease or cancer
20 diagnosis and monitoring of drug therapy.

The present invention provides a method for producing monoclonal antibodies against human collagens Types I through VI, the collagen degrading enzyme elastase and the 1(III)^B peptide cleaved from Type III collagen
25 by elastase. The monoclonal antibodies may be used in standard radioimmunoassays or enzyme-linked immunosorbent assays for the quantitative measurement of the spectrum of connective tissue proteins in a given sample of body
30 fluid, thereby permitting non-invasive diagnosis of certain pathological states and the monitoring of therapies that result in release of connective tissue proteins into sera and other biological fluids. The monoclonal antibodies may be tagged with compounds which
35 fluoresce at various wavelengths so that the distribution of collagens in tissue biopsies can be determined by



immunohistological techniques. Radioimmunoassays and immunohistological methods employing the monoclonal antibodies of this invention can be used to detect and follow the pathogenesis of diseases, such as: genetic disorders affecting skeleton, skin and muscles; formation of excessive scar tissue; and deposition of pathological amounts of connective tissue in body organs, including kidney, intestines and heart, and in liver by liver cirrhosis, in skin by scleroderma; in lung by lung fibrosis; in bone marrow by leukemia; in blood vessels by atherosclerosis; and in joints by rheumatic diseases. The methods involving monoclonal antibodies can also be used to detect changes in the neosynthesis of collagens that is indicative or suggestive of the malignant state of cells derived from such tumors as breast carcinomas.

Because the monoclonal antibodies are produced by hybridoma techniques, the present invention provides theoretically immortal cell lines capable of consistently producing high titers of single specific antibodies against the distinct connective tissue proteins. This is a distinct advantage over the traditional technique of raising antibodies in immunized animals where the resulting sera contain multiple antibodies of different specificities that vary in both type and titer with each animal, and, in individual animals, with each immunization.

The invention contemplates the extension of the hybridoma technique to the production of monoclonal antibodies to other genetically distinct collagens and collagen-associated proteins and enzymes as they become known and their use in the in vitro diagnosis of disorders and cancers involving connective tissue proteins.

The invention further contemplates the use of monoclonal or polyclonal antibodies against connective tissue proteins for in vivo diagnostic and therapeutic purposes. Antibodies produced by either conventional methods or the monoclonal techniques of this invention can be labelled with radioactive compounds, for instance, radioactive iodine, and administered to the patient. The antibodies localize in areas of active collagen neosynthesis such as certain malignant tumors or other tissues undergoing pathological changes involving collagen. The localization of the antibodies can then be detected by emission tomographical and radionuclear scanning techniques; such detection is of diagnostic value. In addition, monoclonal or polyclonal antibodies against connective tissue proteins can be conjugated to certain cytotoxic compounds (radioactive compounds or other therapeutic agents) and can be used for therapeutic purposes, for instance, cancer therapy. The antibodies, targeted for malignant cells expressing the appropriate collagen antigen, localize on or in the vicinity of the individual cells or tumor at which point the conjugated cytotoxic compound takes effect to eradicate the malignant cells.

4. DESCRIPTION OF THE INVENTION

4.1. THE ANTIGENS

The genetically distinct types of collagens and other connective tissue proteins can be derived from a variety of tissue sources throughout the human body. Purification of the collagens has been described in the literature [E. Miller and R. Rhodes, Structural and contractile proteins, in: L. Cunningham and D. Frederiksen (editors), Methods in Enzymology, Academic Press, New York (1981)].



Depending on the antibody desired, any one of these distinct connective tissue proteins is a suitable antigen with which to immunize animals, such as mice or rabbits, to obtain antibody-producing somatic cells for fusion. The choice of animal can influence the type of antibody obtained vis a vis the determinant on the antigen against which the antibody is directed. For example, if antibodies directed toward amino or carboxy terminal determinants are desired, rabbits should be immunized. When rats or mice are immunized, antibodies produced against determinants in the more stable helical portion of the various collagen molecules are usually the result.

4.2. SOMATIC CELLS

Somatic cells with the potential for producing antibody and, in particular, B cells, are suitable for fusion with a B-cell myeloma line. Those antibody-producing cells that are in the dividing plasmablast stage fuse preferentially. Somatic cells may be derived from the lymph nodes and spleens of primed animals. Once-primed or hyperimmunized animals can be used as a source of antibody-producing lymphocytes. Mouse lymphocytes give a higher percentage of stable fusions with the mouse myeloma lines described in Section 4.3. However, the use of rabbit, human and frog cells is also possible.

4.3. MYELOMA CELLS

Specialized myeloma cell lines have been developed from lymphocyte tumors for use in hybridoma-producing fusion procedures [G. Kohler and C. Milstein, Europ. J. Immunol. 6:511-519 (1976); M. Shulman et al., Nature 276:269-270 (1978)].



Several myeloma cell lines may be used for the production of fused cell hybrids, including X63-Ag8, NSI-Ag4/1, MPC11-45.6TG1.7, X63-Ag8.653, Sp2/0-Ag14, FO, and S194/5XXO.BU.1, all derived from mice, including MOPC-21 mice, 210.RCY3.Ag1.2.3 derived from rats and U-226AR, and GM1500GTGAL₂, derived from rats and U-226AR, and GM1500GTGAL₂, derived from humans. [G.J. Hammerling, U. Hammerling and J.F. Kearney (editors), Monoclonal antibodies and T-cell hybridomas in: J.L. Turk (editor) Research Monographs in Immunology, Vol. 3, Elsevier/North Holland Biomedical Press, New York (1981)].

4.4. FUSION

Methods for generating hybrids of antibody-producing spleen or lymph node cells and myeloma cells usually comprise mixing somatic cells with myeloma cells in a 2:1 proportion (though the proportion may vary from about 20:1 to about 1:1), respectively, in the presence of an agent or agents that promote the fusion of cell membranes. It is preferred that the same species of animal serve as the source of the somatic and myeloma cells used in the fusion procedure. Fusion methods have been described by Kohler and Milstein [Nature 256:495-497 (1975) and Eur. J. Immunol. 6:511-519 (1976)], and by Gefter et al. [Somatic Cell Genet. 3:231-236 (1977)]. The fusion-promoting agent used by those investigators were Sendai virus and polyethylene glycol (PEG), respectively. The fusion procedure of the example of the present invention is a modification of the method of Gefter et al. [*supra*]; PEG is added to the mixture of mouse spleen and myeloma cells to promote the formation of fused cell hybrids. Dimethyl sulfoxide (DMSO), another agent affecting cell membranes, may also be included, in addition to PEG, in the fusion mixture.

4.5. ISOLATION OF CLONES AND ANTIBODY DETECTION

Fusion procedures usually produce viable hybrids at very low frequency. The frequency of heterokaryon formation using state-of-the art techniques with PEG as fusing agent is generally 1×10^{-2} . Ensuing nuclear fusion and formation of synkaryons has a frequency of 1×10^{-3} . Thus only one in 10^5 fused cells under optimal conditions will yield a viable hybrid cell line. This frequency, when multiplied by the average frequency of the specific plaque-forming cells in spleen (1×10^{-3}) yields an overall "success" expectation of about 1×10^{-8} . Therefore, one immune mouse spleen, containing $1-2 \times 10^8$ cells, should yield at least one specific hybridoma clone [G. J. Hammerling et al., supra].

Because of the low frequency of obtaining viable hybrids, it is essential to have a means of selecting the fused cell hybrids from the remaining unfused cells, particularly the unfused myeloma cells. Generally, the selection of fused cell hybrids is accomplished by culturing the cells in media that support the growth of hybridomas but prevent the growth of the myeloma cells which normally would go on dividing indefinitely. In the example of the present invention, myeloma cells lacking hypoxanthine phosphoribosyl transferase (HPRT⁻) are used. These cells are selected against in hypoxanthine/aminopterin/ thymidine (HAT) medium, a medium in which the fused cell hybrids survive due to the HPRT-positive genotype of the spleen cells. The use of myeloma cells with different genetic deficiencies (e.g., other enzyme deficiencies, drug sensitivities, etc.) that can be selected against in media supporting the growth of genotypically competent hybrids is also possible.

Generally, around 3% of the hybrids obtained produce the desired antibody, although a range of from 1 to 30% is not uncommon. The detection of antibody-producing hybrids can be achieved by any one of several standard assay methods, including enzyme-linked immunoassay and radioimmunoassay techniques which have been described in the literature [R. Kennet, T. McKearn and K. Bechtol (editors), Monoclonal antibodies, hybridomas: a new dimension in biological analyses, pp. 376-384, Plenum Press, New York (1980)]. The detection method used in the example of the present invention was an enzyme-linked immunoassay employing an alkaline phosphatase-conjugated anti-mouse immunoglobulin.

15

4.6. CELL PROPAGATION AND ANTIBODY PRODUCTION

Once the desired fused cell hybrids have been selected and cloned into individual antibody-producing cell lines, each cell line may be propagated in either of two standard ways. A sample of the hybridoma can be injected into a histocompatible animal. The injected animal develops tumors secreting the specific monoclonal antibody produced by the fused cell hybrid. The body fluids of the animal, such as serum or ascites fluid, can be tapped to provide monoclonal antibodies in high concentration. Alternatively, the individual cell lines may be propagated in vitro in laboratory culture vessels.

20
25

30

4.7. IN VITRO DIAGNOSTIC USES FOR MONOCLONAL ANTIBODIES TO CONNECTIVE TISSUE PROTEINS

In Section 2.3., supra, pathological conditions involving connective tissue proteins were enumerated and the changes in collagen profiles of affected tissues and body fluids that occur as the diseases progress were

35



discussed. To illustrate how monoclonal antibodies against specific collagens can be used to diagnose pathological conditions in humans, the following three examples involving 1) non-invasive serological diagnosis of disease, 2) histological diagnosis of disease and 3) cancer detection are offered.

Rheumatoid arthritis and osteoarthritis synovial fluid may be withdrawn from the knee which can be subjected to radioimmunoassays (and immunofluorescent assays for any cell which may be present in the fluid) in which monoclonal antibodies against the various types of collagen are used. If Type II collagen, for instance, is detected in the synovial fluid, this may indicate the destruction of articular cartilage which is characteristic of osteoarthritis, but which also occurs in other erosive joint disorders. On the other hand, if Types I and III collagens are detected, this may be more indicative of the inflammatory-proliferative phase of rheumatoid arthritis. The ability to diagnose early lesions of articular cartilage can effect the choice of the appropriate therapy with which to treat the patient.

The application of monoclonal antibodies conjugated to fluorophores that fluoresce at variable wavelengths to various tissue sections represents a sensitive means of detecting changes in the collagen distribution within biopsied tissue samples. For instance, if liver cirrhosis is suspected, part of the affected tissue can be immunohistologically stained with monoclonal antibodies against Types I, III and IV collagens. Normally, liver contains very little collagen; thus a lack of significant fluorescent staining would indicate a healthy liver. On the other hand, if Type IV collagen was detected in the sample, this would suggest

the early stages of cirrhosis. Similarly, if the monoclonal antibodies against Types III and I collagens detected the deposition of such collagens, this would suggest the more advanced stages of the fibrotic disease. [It should be noted that fibrotic diseases affecting the liver and the connective tissue of the organs such as skin and bone can also be detected by serological (i.e., non-biopsy) means utilizing monoclonal antibodies on serum samples.]

One of the most important applications of monoclonal antibodies against connective tissue proteins is for the purpose of early and accurate cancer diagnosis. For example, malignant epithelial cells of breast carcinomas actively produce basement membrane (Type IV) collagen. The production of this collagen continues as the cell metastasizes to other locations, such as the lymph nodes surrounding the breast area. With monoclonal antibodies against Type IV collagen, the presence of a single metastasized cell can be detected immunohistologically in a lymph node biopsy. An early diagnosis of infiltrating cells and lymph node metastasis as judged on the basis of as little as one basement membrane collagen-synthesizing tumor cell is of significant prognostic importance.

Other types of malignancies may also be diagnosed by detecting the neosynthesis of collagens. For instance, monoclonal antibodies against collagens may also prove useful for locating malignant cells in cytological samples such as in Pap smears taken to diagnose cervical and/or uterine cancers. Monoclonal antibodies may also be used in immunohistological differential diagnoses to distinguish, for example, malignant melanomas from benign naevi.

4.8. THERAPY MONITORING USING MONOCLONAL ANTIBODIES AGAINST CONNECTIVE TISSUE PROTEINS

5

Monoclonal antibodies against connective tissue proteins may be used to monitor the effectiveness of antifibrotic drug therapies. They provide the immunoserological, immunohistological and immunocytological means to detect an inhibition or suppression of collagenous connective tissue neosynthesis, the resulting diminution in the accumulation of the collagenous matrix, and hence, the antifibrotic effect of the drug.

15

Similarly, monoclonal antibodies may be used to monitor the effectiveness of certain chemotherapies aimed at eradicating malignant tumor cells. For example, tumor cells present in bone marrow malignancies produce the enzyme elastase which selectively cleaves one fourth of the Type III collagen molecule to yield a peptide fragment. If such cells are successfully destroyed by chemotherapeutic means, both elastase and the Type III peptide fragment are released and enter the serum. Detection of this enzyme and peptide in serological samples using monoclonal antibodies provides a sensitive and non-invasive means for monitoring the efficacy of anti-tumor drug therapies.

30

4.9. ANALYTICAL METHODS

4.9.1. RADIOIMMUNOASSAY

A radioactively labeled connective tissue protein is mixed with monoclonal antibodies specific for that particular protein as antigen and with a serological

35



sample containing an unknown amount of unlabeled connective tissue protein. The labeled and unlabeled antigen compete for binding with the monoclonal antibody. The more unlabeled connective tissue protein there is in the serological sample, the less labeled antigen binds with antibody to form an insoluble complex. By measuring the amount of radioactivity associated with either the insoluble or soluble fractions of the reaction mixture and comparing the values obtained with an appropriately constructed calibration curve (wherein in known amounts of unlabeled and labeled antigen were reacted with antibody), the amount of connective tissue protein in the sample can be accurately quantitated.

15

4.9.2. ENZYME-LINKED IMMUNOSORBENT ASSAY

Connective tissue proteins in serological samples can be measured by a variation of the enzyme-linked immunosorbent assay (ELISA) used to screen hybrids for antibody production (see Section 4.5). Enzyme immunoassays (EIA) are based on the principle of competitive binding as described in Section 4.9.1 for radioimmunoassay (RIA). The procedures differ in that an enzyme is used as the "label" in EIA as opposed to a radioisotope as in RIA.

25

4.9.3. IMMUNOHISTOLOGICAL AND IMMUNOCYTOLOGICAL STAINING

30

Slides containing cryostat sections of frozen, unfixed tissue biopsy samples or cytological smears are air dried and incubated with a single monoclonal antibody preparation. The slides are then layered with a preparation of antibody directed against the monoclonal antibody. This anti-monoclonal antibody immunoglobulin is

35



tagged with a compound that fluoresces at a particular wavelength for instance rhodamine. If it is desirable to immunohistologically (or immunocytoologically) stain for more than one type of connective tissue protein in a given sample, the slide is then layered with another coating of a second type of monoclonal antibody. This is followed by the application of a second anti-monoclonal antibody immunoglobulin tagged with a compound that fluoresces at a different wavelength than the first fluorophore, such as fluorescein isothiocyanate, and so on until all the connective tissue proteins have been stained. The localization of the connective tissue proteins within the sample is then determined by fluorescent light microscopy and optionally photographically recorded.

4.9.4. IMMUNOELECTRONMICROSCOPY

Under some circumstances it may be necessary to use immunoelectronmicroscopy to detect the presence of collagen and other connective tissue proteins in histological samples. [See, e.g., D. Engel et al., Archs oral Bio. 25:283-296 (1980)].

5. EXAMPLES

5.1. CONSTRUCTION OF HYBRIDOMAS SECRETING MONOCLONAL ANTIBODIES TO CONNECTIVE TISSUE PROTEINS

The cell hybridization techniques of this invention are adopted from the protocol of Drs. J. Kearney, A. Anderson and P. Burrows, of the Cellular Immunobiology Unit, 224 Tumor Institute, University of Alabama in Birmingham. [G.J. Hammerling, U. Hammerling and J.F. Kearney (editors), Monoclonal antibodies and

T-cell hybridomas in: J.L. Turk (editor), Research Monographs in Immunology, Vol. 3, Elsevier/North Holland Biomedical Press, New York (1981)].

5

5.1.1. PURIFICATION OF CONNECTIVE TISSUE PROTEINS

Methods for the preparation of the individual types of collagens have been described extensively by Miller and Rhodes [Structural and contractile proteins, 10 in: L. Cunningham and D. Frederiksen (editors), Methods in Enzymology, Academic Press, New York (1981)].

The method used to isolate and purify the 15 collagen-degrading enzyme, elastase, is a modification of the procedure of Mainardi et al. [J. Biol. Chem. 255(24): 12006-12010 (1980)].

5.1.2. IMMUNIZATION SCHEDULES

20

At 5 to 6 weeks of age, e.g., BALB/c female mice (Jackson Laboratories) are immunized with 200 ug of a purified connective tissue protein as antigen. The antigen is delivered in 0.5 ml of complete Freund's 25 adjuvant by subcutaneous inoculation. An immunization schedule is followed wherein the mice are boosted intraperitoneally with a similar amount of antigen 21 days after the initial priming. Only a single boost is administered, though other immunization schedules with multiple boosts may be used with similar success. The 30 spleens and lymph nodes are removed 4 days after the booster inoculation following standard techniques [Linsenmayer, T.F., Hendrix, M.J.C. and Little, C.D., Proc. Natl. Acad. Sci. U.S.A. 76:3703-3707 (1979)].

35



5.1.3. SPLEEN CELL PREPARATION

Spleens of immunized BALB/c mice are removed
5 under sterile conditions and washed in serum-free RPMI
1640 medium (Seromed, Munchen, F.R.G.). The spleens are
macerated through cheesecloth and are then resuspended in
serum-free RPMI 1640 medium and centrifuged; this washing
procedure is performed three times at 4°C. After the
10 final washing, the cells are resuspended in the same
medium in a 50 ml sterile tube. The number of cells in
the preparation is determined microscopically before
mixing with myeloma cells for fusion (see Section 5.4).

15 5.1.4. MYELOMA CELL PREPARATION

A variant subclone of the mouse myeloma cell line
P3-X63-Ag8, isolated by Kearney, et al. [J. Immunol.
123(4):1548-1550 (1979)] and designated X63-Ag8.653, is
20 maintained in Dulbecco's MEM or RPMI 1640 medium (Seromed,
Munchen, F.R.G.) supplemented with 15% fetal calf serum,
2 mM glutamine, 50 uM 2-mercaptoethanol (Merck, Darmstadt,
F.R.G.), 100 units/ml penicillin, 100 ug/ml streptomycin,
and 0.25 ug/ml Fungizone (Flow Laboratories, Bonn,
25 F.R.G.) (hereinafter called "complete medium"). Like its
parent, X630-Ag8.653 is a hypoxanthine/aminopterin/
thymidine-(HAT)-sensitive cell line. However, unlike its
parent, X63-Ag8.653 has lost immunoglobulin expression
entirely and does not synthesize L or K chains of X63
30 origin upon fusion with antibody-forming cells. The
myeloma cells are cultured in complete medium and
harvested during the exponential phase of growth.
Harvested cells are transferred to 50 ml sterile tubes and
are washed three times in serum-free RPMI 1640 medium at
4°C. The cells are counted microscopically prior to
35 fusion with spleen cells.

5.1.5. FUSION PROCEDURE

Spleen cells and X63-Ag8.653 myeloma cells are
5 combined in a ratio of 2:1 or 1:1 (spleen cells:myeloma
cells) and washed once in serum-free RPMI 1640 medium at
37°C. The cell mixture is centrifuged at room temperature
at 1,000 rpm for 7 minutes. The pellet fraction is
carefully aspirated to leave it as dry as possible. Next,
10 the pellet is loosened by gentle tapping and is
resuspended with gentle agitation in 1.0 to 1.5 ml of
PEG-4000 (polyethylene glycol) solution at 37°C. The
PEG-400 solution is prepared by autoclaving 20 gm PEG 4000
in a 100 ml bottle, cooling and adding 28 ml of sterile
15 phosphate buffered saline. After approximately 30
seconds, the cell mixture is slowly diluted dropwise to a
volume of roughly 20 ml with serum-free RPMI 1640 medium
at 37°C; the tube is then filled to 50 ml with the same
medium. The cells are centrifuged at room temperature and
20 resuspended at 37°C in HAT medium, which is selective for
fused cells. HAT medium is prepared by adding 1 ml of a
stock solution (100X) of hypoxanthine (H) and thymidine
(t) and 1 ml of a stock solution (100X) of aminopterin (A)
to 100 ml of complete medium. The HT stock contains 272.2
25 mg hypoxanthine and 7.75 mg thymidine in 200 ml distilled
water. Because the hypoxanthine does not dissolve well,
the pH of the solution is adjusted to pH 8.1-8.5 with 1-2
drops of 1N NaOH. The solution is sterilized through a
0.45 u Millipore filter and stored at 4°C. The A stock
30 contains 3.52 mg aminopterin in 200 ml distilled water.
It is also sterilized by Millipore filtration and stored
at 4°C.

The cell mixture is resuspended in HAT medium at
a concentration of about $2 \text{ to } 5 \times 10^5$ spleen cells/ml.
35 Care is taken not to break up cell clumps. Peritoneal

exudate feeder cells are then added (roughly, the peritoneal washout of one normal, non-immunized mouse per 100 ml of HAT/fused-cell suspension) and 1 ml of the cell suspension is added per well of a 24 well macrotiter plate (Costar, Cambridge, Massachusetts).

5.1.6. OUTGROWTH AND SELECTION

After 4 or 5 days in the selective HAT medium, the cells are observed with an inverted microscope to check for myeloma cell death. (The X63-Ag8.653 cell line is HAT-sensitive and thus, unfused myeloma cells cannot survive in this medium; unfused spleen cells naturally die out of the culture.) Contamination of the wells is also checked for and any contaminated wells are killed with a copper sulfate solution.

The fused cells are allowed to incubate in HAT medium for two weeks at which time 0.5 ml of the supernatant of each well is discarded and replaced with 0.5 ml of complete (non-HAT) medium. This medium replenishment is repeated daily for another week. Two to three days after the last medium replenishment, which is enough time to allow for sufficient production of antibodies for testing, the macrotiter plates are scored for hybrid growth and assayed for antibody activity by the ELISA method described in Section 5.1.7.

5.1.7. IMMUNOLOGICAL CHARACTERIZATION OF HYBRID-PRODUCED MONOCLONAL ANTIBODIES

The identification of those hybrids synthesizing antibodies which recognize the connective tissue protein used as antigen is accomplished using a modification of the enzyme-linked immunosorbent assay (ELISA) [Engvall, E.



and Perlman, P., *Immunochem.* 8:871-876 (1971)] as detailed by Kearney et al. [*J. Immunol.* 123:1548-1550 (1979)].

5 The wells of a 96-well polyvinyl microtiter plate are coated with 100 ul/well of 1 mg/ml solution of collagen antigen in borate saline. The plate is incubated for four hours at 25°C or overnight and 4°C. The plates are then blocked with 1% bovine serum albumin (BSA) in
10 borate buffered saline (BS-BSA) and incubated for one hour at 25°C. The wells of the microtiter plate are washed twice with saline, after which the supernatants (containing monoclonal antibodies) from the wells of the
15 microtiter plates used for outgrowth and selection of fused hybrids are added to the microtiter wells. The plate is incubated for four hours at 25°C (or overnight at 4°C) and washed two to three times with saline. To each well, 100 ul of alkaline phosphatase-labeled antibodies (goat antimouse-immunoglobulin) diluted 1:500 in BS-BSA is
20 added. After incubating for four hours at 25°C or overnight at 4°C, the wells are washed 4-5 times with saline and 200 ul of substrate (p-nitrophenylphosphate) is added per well. The reaction is stopped by the addition of 50 ul 3 N NaOH to each well. The absorbance of the
25 fluid in the wells is then determined spectrophotometrically.

 In those wells to which monoclonal antibodies from the culture supernatants bind and to which the
30 enzyme-linked goat antimouse-immunoglobulin subsequently bind, the alkaline phosphatase converts colorless p-nitrophenylphosphate into yellow p-nitrophenol. The colorimetric reaction permits the easy identification of those culture supernatants containing collagen-specific
35 antibodies and hence the identification of the desired fused hybrids. This step is performed to exclude from



further analysis those hybrids that do not produce immunoglobulin and those that synthesize antibodies not specific for the collagen protein antigen.

5

5.1.8. CLONING OF HYBRIDS

The extent of hybrid cell growth in the wells of the microtiter plates (see Section 5.1.6.) is determined 3-4 weeks after the initial plating in HAT medium. The cell suspensions were agitated gently and 2-5 ul are diluted from each well into 30 ml of complete medium containing peritoneal exudate feeder cells. Into each well of a 96-well costar microtiter plate, 200 ul of the diluted cell suspension are distributed. This suspension is diluted further by delivering 10 ml in 20 or 30 ml of medium containing feeder cells and 200 ul aliquots are added to each well of another microtiter plate. Further dilutions of the cell suspension can be performed if necessary. This method is used to insure that the wells of at least one plate contain clones derived from a single cell. Samples of cells from the original hybridoma-containing microtiter wells are frozen for safekeeping.

25

After a sufficient time for growth of the hybridoma cells (clones), the supernatants of the microtiter wells are rescreened for monoclonal antibody production using the ELISA assay described in Section 5.1.7.

30

5.1.9. STABILITY OF PHENOTYPE DETERMINATION

Those hybrids identified to be specific antibody producers are transferred to new Costar plates at low cell density (approximately 5 cells/well). Surviving hybrids

35

are screened and those continuing to demonstrate antibody production are recloned to insure that the antibodies produced arise from a single fused hybrid and hence are monospecific.

5.1.10. DETERMINATION OF MONOCLONAL ANTIBODY SPECIFICITY

The culture media from hybrids that survived two successive clonings and that continued to exhibit a stable phenotype are screened for cross-reactivity against the other types and individual molecular forms of collagen as well as other connective tissue proteins using the ELISA assay of Section 5.1.7. Instead of using the antigen against which the monoclonal antibody was raised to coat the wells of the Costar plates, the other individual collagens and connective tissue proteins are used in the ELISA assay. Only those monoclonal antibodies exhibiting no cross-reactivity are used in the procedures for detecting connective tissue proteins in body fluids and tissue samples described in Sections 5.2, 5.3, and 5.4 below.

5.1.11. PROPAGATION OF HYBRID CELLS AND ANTIBODY PRODUCTION

Hybrids which synthesized antibodies of the desired specificity are amplified in cell culture and stored in liquid nitrogen so that an adequate supply of cells producing identically monospecific antibodies are available. To propagate the hybrids, samples of the fused cells are injected intraperitoneally into BALB/c mice (10^6 cells/mouse) resulting in the subsequent induction of palpable tumors within a few weeks. The tumors generally produce ascites fluid (approximately 2 ml per mouse) containing antibody amounts significantly greater

(as high as 60 mg per mouse) than those obtained by in vitro cell culture techniques. Sera samples from the inoculated mice contain antibody titers comparable to that of ascites fluid. The mouse hybridoma-produced monoclonal antibodies are purified by subjecting samples of ascites fluid, sera, or media to immunoabsorption chromatography.

10 5.2. DETECTION AND MEASUREMENT OF
CONNECTIVE TISSUE PROTEINS IN
BIOLOGICAL FLUIDS WITH MONOCLONAL
ANTIBODIES

15 5.2.1. RADIOIMMUNOASSAY

15 Iodinated connective tissue protein antigens are prepared as described by Rohde et al. and are used in a modification of the radioimmunoassay described by the same authors [J. Immunol. Meth. 11:135-145 (1976)]. Antibody
20 titrations are carried out by diluting the monoclonal antibody preparation with PBS. Duplicate tubes containing 0.1 ml monoclonal antibody preparation (ascites fluid or tissue culture fluid), 0.1 ml labeled antigen, and 0.2 ml 1% BSA dissolved in PBS are incubated for 24 hours at 4°C. After mixing with 0.5 ml antiserum to mouse Ig, the
25 incubation is continued for an additional 24 hours at 4°C. Insoluble material is collected by centrifugation and the precipitate is washed three times with cold PBS/BSA prior to counting. Non-specific precipitation of labeled antigen is determined by replacing the monoclonal
30 antibody preparation by non-immune Ig. Antigen binding capacity of the monoclonal antibody preparation is calculated according to Minden and Farr [D.M. Weir, (editor) Handbook of Experimental Immunology, Blackwell, Oxford, England, p. 151].
35

In the competition assay, sufficient monoclonal antibody is used to bind 80% of the labeled antigen. However, the monoclonal antibody preparation is first incubated with a sample containing unlabeled connective tissue protein at 4°C for 24 hours and then the labeled antigen is added to the reaction, followed by incubation and finally addition of and incubation with anti-mouse Ig as above. Precipitable counts are measured, also as above in a Beckman Gamma 300 counter.

5.2.2. ENZYME-LINKED IMMUNOSORBENT ASSAY

Monoclonal antibodies directed against connective tissue proteins are conjugated to alkaline phosphatase by the method of Hammerling et al. [Monoclonal antibodies and T-cell hybridomas in: J.L. Turk (editor) Research Monographs in Immunology, Vol. 3, Elsevier/North Holland Biomedical Press, New York (1981)]. Dialysis tubing is boiled for 20 minutes in deionized water. Alkaline phosphatase (1.5 mg as an ammonium sulfate-precipitated slurry) is centrifuged at 4°C for 2-3 minutes at 12,000xg and the supernatant is discarded. The pelleted enzyme is dissolved in buffer (Dulbecco's PBS with magnesium and calcium cations, DPBS) containing an appropriate amount of monoclonal antibody, in a volume of approximately 0.2 ml. The antibody-enzyme mixture is dialyzed against 100 ml of DPBS overnight at 4°C. The contents of the dialysis tubing are washed out into a graduated glass tube and the volume is adjusted to 0.5 ml with DPBS. Next, 25% glutaraldehyde is added to a final concentration of 0.2% (4 ul for 0.5 ml). The mixture is gently agitated on a Vortex mixer and is incubated for 2 hours at room temperature. After dialyzing overnight against DPBS at 4°C, the enzyme-coupled antibody is diluted to 10 ml with 5% BSA-0.05 M Tris buffer, which serves as a stock solution.

Enzyme-linked monoclonal antibodies thus prepared are mixed with serological samples containing unknown amounts of the specific connective tissue protein being
5 assayed. The mixtures are transferred to the wells of microtiter plates pre-coated with the appropriate antigen and the enzyme activity of the conjugated alkaline phosphatase is measured as described in Section 5.1.7.

10 5.3. IMMUNOHISTOLOGICAL APPLICATION OF
MONOCLONAL ANTIBODIES AGAINST
CONNECTIVE TISSUE PROTEINS

15 5.3.1. IMMUNOFLOUORESCENT STAINING OF
BIOPSIED TISSUE SECTIONS

Sections of tissues 4-6 um thick are prepared from frozen, unfixed biopsy samples by cryostat sectioning. The air-dried sections are incubated with a
20 particular monoclonal antibody. For controls, sections are incubated with immunoglobulin (Ig) from pre-immune serum. After 30 minutes of incubation in a humidified chamber at room temperature, the sections are rinsed three
25 times with phosphate-buffered saline (PBS, pH 7.4) and, in a second step, layered with a 1:30 dilution of fluorescein-isothiocyanate conjugated (FITC) rabbit
anti-mouse Ig for 30 minutes. Finally, the slides are washed exhaustively to remove nonspecifically associated reagents and are sealed with a solution of 90%
30 glycerol/10% PBS under a coverslip. The localization of staining is observed and photographed using a Leitz-fluorescence microscope equipped with a K2 filter system for FITC.

5.3.2. IMMUNOELECTRONMICROSCOPY

Immunoelectronmicroscopy is performed according
5 to [R. Fleischmajer et al., J. Invest. Dermat. 75:189-191
(1980)] and [Gay et al., Collagen Rel. Res. 1:370-377
(1981)]. Tissues, for instance kidney, are fixed in
phosphate buffered 4% paraformaldehyde at 4°C for 2 hours
with one change. Tissues are then washed for 36 hours in
10 PBS with 4% sucrose at 4°C with multiple changes. The
last wash is performed in PBS with 4% sucrose and 5%
glycerol for 1 hour. Tissues are then placed in OCT
freezing medium with a cork or plastic backing to hold
them and quickly frozen by immersing them in a jar of
15 methylbutane (isopentane) placed in a small chamber of
liquid nitrogen. The frozen tissues are then wrapped in
aluminum foil and stored in a closed container at -20°C.
Frozen sections 8 um thick are cut and placed in albumin
coated slides and air-dried for at least 5 minutes.
20 Slides are then placed in a solution of ice-cold NaBH_4
(10 mg/100 ml) in PBS for 1 hour with one change.
Following this procedure, the slides are washed at 4°C in
PBS, 3 changes for 30 minutes each.

25 Tissue sections are reacted with the appropriate
monoclonal antibody in a moist chamber overnight at 4°C or
at room temperature for 2 hours. Slides are washed
thoroughly with PBS and then incubated an additional 2
hours with secondary antibody (goat or rabbit anti-mouse
30 Ig). This is followed by washing with cold PBS and a
third antibody treatment with Fab-peroxidase-
anti-peroxidase (Fab-PAP) for 3 hours. The Fab-PAP
solution is removed by washing with PBS and the tissue
sections are incubated in 150 ml of 0.1 M Tris, pH 7.6,
35 containing 40 mg of 3,3-diaminobenzidine
tetrahydrochloride and 15 ul of 5% H_2O_2 for 15-18
minutes. Slides are then washed with cold PBS and stained

with 1% osmium tetroxide for 1 hour at room temperature. The stained slides are again rinsed with cold PBS, dehydrated in acetone, embedded in Maraglas^R (70%) and ultra-thin sections are made for examination using a Zeiss EM 10 electron microscope.

5.4. IMMUNOCYTOLOGICAL APPLICATION OF
MONOCLONAL ANTIBODIES AGAINST
CONNECTIVE TISSUE PROTEINS

To determine the production of collagens and the type of collagen synthesized by cells such as skin fibroblasts which can be cultivated in vitro by standard cell culture techniques, the following procedure is used. Anchorage-dependent cells which have grown to confluent monolayers on solid supports are detached by exposure to trypsin and are replated in the Dulbecco-Vogt modification of Eagle's medium containing 10% fetal calf serum in 35 x 10 mm Falcon plastic tissue culture dishes. The dishes are incubated at 37°C under a 5% CO₂/95% air atmosphere. About 6 hours later, the medium in each dish is replaced with fresh media which in some cases contained 50 ug/ml of newly dissolved ascorbic acid. These media are replaced every day. At various times after plating the cells, dishes are taken for analysis, the media are removed, and the dishes are rinsed at least four times with 0.15 M NaCl, 0.05 M Tris-HCl pH 7.4.

The air-dried culture dishes are rinsed with acetone and allowed to dry. Purified monoclonal antibodies dissolved in 0.15 M NaCl, 0.02 M sodium phosphate, pH 7.4, are added to the dishes and allowed to react for 2 hours at 20°C. Controls are run to assess the nonspecific associations of reagents with the cells. Such control experiments indicated that the nonspecific

association of label is negligible. Subsequently, the dishes are rinsed three times with 0.15 M NaCl, 0.02 M sodium phosphate, pH 7.4, and are layered with 1 ml of a
5 1:32 dilution of fluorescein-isothiocyanate-conjugated rabbit antimouse Ig. When cell samples are simultaneously stained for two antigens, the dishes are first exposed to one type of monoclonal antibody against a connective tissue protein and then to the fluorescein-isothiocyanate-
10 conjugated rabbit antimouse Ig. Subsequently, the dishes are exposed to monoclonal antibodies against a different type of connective tissue protein, washed, and then reacted with rhodamine-conjugated rabbit antimouse Ig. Finally, all dishes are washed extensively to remove
15 adventitiously associated reagents and sealed from the air with a solution of 90% glycerol/10% saline under a cover slip. The localization of fluorescent stains on the dishes is observed in a Zeiss Universal fluorescence microscope and recorded photographically.

I Claim:

1. A process for producing an antibody against a
5 connective tissue protein, comprising: propagating a fused
cell hybrid constructed by fusing a cell which produces
antibodies against a connective tissue protein and a
myeloma cell and collecting said antibodies.
- 10 2. The process of claim 1 wherein said
connective tissue protein is selected from the group
consisting of human Type I, Type II, Type III, Type IV,
Type V or Type VI collagen, procollagen, collagen peptide
and procollagen peptide.
- 15 3. The process of claim 1 wherein said
connective tissue protein is human collagenase.
- 20 4. The process of claim 3 wherein said
collagenase is elastase.
5. The process of claim 1 wherein said hybrid is
propagated in vitro or in a histocompatible animal.
- 25 6. The process of claim 1 wherein said
antibody-producing cell is selected from the group
consisting of spleen cells and lymph node cells.
- 30 7. The process of claim 6 wherein said spleen is
mouse spleen and said lymph node is mouse lymph node.
8. The process of claim 1 wherein said myeloma
is mouse myeloma.
- 35 9. The process of claim 8 wherein said myeloma
is X63-Ag8.653.



10. A process for producing an antibody against a connective tissue protein, comprising: propagating a fused cell hybrid constructed by fusing an anti-connective tissue protein antibody-producing cell from an BALB/c mouse immunized with said connective tissue protein and an X63-Ag8.653 myeloma cell and collecting said anti-connective tissue protein antibodies.

11. The method of claim 10 wherein said hybrid is propagated in vitro or in vivo.

12. A continuous cell line which produces antibodies against a connective tissue protein, comprising: a fused cell hybrid of a cell which produces antibodies against a connective tissue protein and a MOPC-21 mouse myeloma cell.

13. A monoclonal antibody against a connective tissue protein produced by the method of claim 1.

14. A method for detecting human pathological conditions involving connective tissue proteins, comprising: contacting monoclonal antibodies of claim 13 with a human tissue or fluid sample, and detecting the interaction of said antibodies with any antigenically corresponding connective tissue proteins in said sample to obtain a collagen profile.

15. The method of claim 14 wherein said sample is a biological fluid sample, a histological sample, or a cytological sample.

16. The method of claim 14 wherein said human pathological condition is a heritable connective tissue disorder.

5

17. The method of claim 14 wherein said human pathological condition is a healing disorder.

18. The method of claim 17 wherein said healing disorder is a skin wound healing disorder, a tendon healing disorder or a bone fracture healing disorder.

10

19. The method of claim 14 wherein said human pathological condition is atherosclerosis, liver cirrhosis, lung fibrosis, systemic progressive sclerosis, rheumatoid arthritis, osteoarthritis, myelofibrosis, leukemia, or cervical cancer.

15

20. The method of claim 14 wherein said human pathological condition is a human cancer characterized by a tumor in which changes in collagen profile have occurred.

20

21. The method of claim 20 wherein said human cancer is breast carcinoma, cervical carcinoma, osteosarcoma, chondrosarcoma, myosarcoma or neurofibrosarcoma.

25

22. The method of claim 14 wherein said interaction is detected by radioimmunoassay or enzyme-linked immunosorbent assay.

30

23. The method of claim 14 wherein said interaction is detected by immunohistological staining.



24. The method of claim 23 wherein said immunohistological staining is observed by fluorescence microscopy or electron microscopy.

5

25. A method for monitoring the status of a human pathological condition involving connective tissue proteins comprising: comparing a collagen profile of a first sample of a tissue or body fluid from an individual with a second sample of the same type of tissue or body fluid from said individual, wherein the second sample is taken subsequent to the first sample and the collagen profiles are obtained by a method of claim 14.

10

26. A method of claim 25 wherein said human is under therapeutic treatment for a fibrotic disease or under chemotherapeutic treatment for cancer.

15



INTERNATIONAL SEARCH REPORT

International Application No. PCT/US 83 / 0 0 7 4 . 1

I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all) *

According to International Patent Classification (IPC) or to both National Classification and IPC

IPC. CL. G01N 33/54, C12N 5/00, C12P 21/00

II. FIELDS SEARCHED

Minimum Documentation Searched *

Classification System

Classification Symbols

US

436/536-548
435/4, 7, 68, 172, 240
424/ 1, 1.5

Documentation Searched other than Minimum Documentation
to the Extent that such Documents are Included in the Fields Searched *

Databases: Biosis, Medline

Keywords: Antibody, Monoclonal, Hybridoma, Collagen!,
Procollagen, Elastinase, "Gay, Steffen"

III. DOCUMENTS CONSIDERED TO BE RELEVANT ¹⁴

Category *	Citation of Document, ¹⁵ with indication, where appropriate, of the relevant passages ¹⁷	Relevant to Claim No. ¹⁸
A	US, 4,312,853, Published 26 January 1982, Timpl, R.	1-26
X	N, Federation Proceedings Volume 40, (3 Part 1), page 794, abstract 3213, Issued 1981, Foellmer et al.	1-26
X	N, Federation Proceedings Volume 41, (Number 3), page 616, abstract 2027, Issued 1982, Foellmer et al.	1-26
X	N, Proceeding of the National Academy of Sciences, USA, Volume 76 (Number 8) pages 3703-3707, Issued August 1979, Linsemayer et al.	1-26

* Special categories of cited documents: ¹⁶

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"Δ" document member of the same patent family

IV. CERTIFICATION

Date of the Actual Completion of the International Search *

5 July 1982

Date of Mailing of this International Search Report *

15 JUL 1983

International Searching Authority *

ISA/US

Signature of Authorized Officer ¹⁹

TEDDY S. GRON

EXAMINER

GROUP ART UNIT 223

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)

Category *	Citation of Document, with indication, where appropriate, of the relevant passages ¹⁷	Relevant to Claim No. 1 ¹⁸
X	N, Biochemical and Biophysical Research Communications, Volume 92 (Number 2), pages 440-446, Issued January 1980, Linsenmayer et al.	I-26
X	N, Anatomical Record, Volume 193 (Number 3) page 605, Issued 1979, Linsenmayer et al.	1-26
X	N, Journal of Cell Biology, Volume 83 (Number 2, part 2), page 463A, abstract x2802, Issued 1979, Linsenmayer et al.	1-26
X	N, Immunology, Volume 47 (Number 1), pages 133-140, Issued 1982, Sundarraj et al.	1-26
X	N, Biochemical and Biophysical Research Communications, Volume 106 (Part 1), pages 48-57, Issued May 1982, Sundarraj et al.	1-26
X	N, Federation Proceedings, Volume 41, (Number 3), page 616, abstract 2026, Issued 1982, Scheinman et al.	1-26